MDWD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MediWound Ltd (MDWD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows potential with its pipeline drug EscharEx and positive analyst ratings, the lack of recent positive financial performance, neutral trading trends, and absence of strong proprietary trading signals suggest holding off on immediate investment. The investor may consider revisiting the stock after further developments in the company's financials or product pipeline.
The MACD histogram is positive and expanding, indicating a potential bullish momentum. However, the RSI is neutral at 50.722, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a lack of strong upward momentum. Key support and resistance levels are Pivot: 14.284, R1: 14.758, S1: 13.81, R2: 15.05, S2: 13.518.
Analysts maintain a positive long-term outlook due to the potential of the pipeline drug EscharEx to drive sustained profitability. The stock has a 60% chance of gaining 5.85% in the next week and 6.37% in the next month.
Recent Q1 results showed lower revenue, impacted by the lack of BARDA and Department of War grants and limited NexoBRID capacity. Analysts have lowered price targets, and the company's full-year revenue guidance is at risk. No significant trading trends or recent news to act as a catalyst.
No detailed financial data available for analysis. However, Q1 results showed lower revenue and a lower loss than expected, with revenue impacted by external factors such as grant timing and product capacity.
Alliance Global lowered the price target to $22 from $25, maintaining a Buy rating. Oppenheimer lowered the price target to $32 from $33, maintaining an Outperform rating. Analysts remain optimistic about the company's long-term potential despite short-term revenue challenges.
